Navigation Links
DATATRAK International Management to Host Conference Call on February 26, 2008 to Discuss Fourth Quarter and Full Year Operating Results for 2007

CLEVELAND, Feb. 19 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (Nasdaq: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced that it will host a conference call to discuss fourth quarter and full year operating results for 2007 at 4:30 p.m. ET on Tuesday, February 26, 2008.

To participate via phone, participants are asked to dial 412-858-4600 a few minutes before 4:30 p.m. ET. The conference call will also be available via live web cast on DATATRAK International, Inc.'s web site by clicking the button labeled "Click here for Live Web Cast, 4th Quarter Earnings Call" on the Company's homepage at a few minutes before 4:30 p.m. ET.

A replay of the phone call and web cast will each be available at approximately 6:30 p.m. ET on February 26, 2008 and will run until 9:00 a.m. ET on March 4, 2008. The phone replay can be accessed by dialing 412-317-0088 (access code 416290). To access the web cast replay go to the Company's homepage at and click the button labeled "Click here for Replay of Web Cast, 4th Quarter Earnings Call."

DATATRAK International, Inc. is a worldwide technology company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 separate drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, Bonn, Germany, and Bryan, Texas. Its common stock is listed on the NASDAQ Stock Market under the ticker symbol "DATA". Visit the DATATRAK International, Inc. web site at

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward- looking statements are made based on management's expectations and beliefs concerning future events impacting the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the Company's success in integrating its acquisition's operations into its own operations and the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement.

SOURCE DATATRAK International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. DATATRAK Closes Second Multi-Year Enterprise Agreement with European Clinical Trial Sponsor
2. DATATRAK to Present at the Roth Capital Partners 20th Annual Orange County Stock Conference
3. DATATRAK International Launches Innovative, Interactive Educational Webcast Series
4. DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results
5. DATATRAK International Management To Host Conference Call on November 8, 2007 To Discuss Third Quarter and Nine Month Operating Results for 2007
6. ORBIS Internationals Flying Eye Hospital Returns to Myanmar
7. Global Med Technologies(R), Inc. Adds Internationally Renowned NewYork- Presbyterian Hospital to Client List
8. Tahitian Noni International Expands HIRO(TM) Beverage Line With Super Fruits Sparkling Black Currant
9. Service Corporation International Declares Quarterly Cash Dividend
10. Healthy Coffee International, Inc. Establishes Healthy Coffee USA, Inc. as Its Marketing Arm
11. 2008 International Conference on Emerging Infectious Diseases
Post Your Comments:
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... my cancer, I found that regular bras were incredibly uncomfortable," said an inventor ... this specialized bra." , She developed the patent-pending RECOVERY BRA for added comfort ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bcureful—a non-profit ... as well as raising public awareness of the disorder while helping to bring ... donation of $35,000 to bolster progress at the Tuberous Sclerosis Complex Center at ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic ... Plan software creates an agreement between the practice owner and the patient that ... monitoring, notification, and projections. Click here to learn more. ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Young patients ... treatments from Dr. Angela Wolfman and Dr. Kedar S. Lele, who are pediatric ... frenectomies, cavities and fillings, the WaterLase iPlus 2.0™ system causes minimal discomfort and bleeding ...
(Date:11/24/2015)... ... November 25, 2015 , ... Catalent Pharma Solutions, the ... consumer health and global clinical supply services, today announced that Dr. Christine Milligan, ... East Asia Conference, to be held at the InterContinental Seoul COEX Hotel, Seoul, ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Frankreich, November 25, 2015 ... bekanntgegeben, dass sie eine Lizenz für das Patent über ... CNRS, UCBL und ENS-Lyon innehaben, an Enyo Pharma vergeben ... FUI AAP8 ins Leben gerufenen und von Edelris gemeinsam ... FXR als ein Behandlungsziel für HBV identifiziert, und es ...
(Date:11/24/2015)... DELHI , November 25, 2015 ... invoked due to repeated failure of IVF cycles. After ... Bhatia was totally dejected and had lost all hopes that she would be ... first Indian miracle child conceived after failure of over ... to abroad (UK) before they decided to take one last attempt ...
(Date:11/24/2015)... 24, 2015  Thanks to a donor with a ... Medical Center,s Sister Diane Grassilli Center for Women,s Health ... San Francisco . ... forward with a gift of $617,320 that allowed the ... with Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, three-dimensional (3-D) ...
Breaking Medicine Technology: